E
E J Baxter
Researcher at Salisbury District Hospital
Publications - 3
Citations - 1767
E J Baxter is an academic researcher from Salisbury District Hospital. The author has contributed to research in topics: Imatinib & Imatinib mesylate. The author has an hindex of 2, co-authored 3 publications receiving 1591 citations.
Papers
More filters
Journal ArticleDOI
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Jyoti Nangalia,Charles E. Massie,E J Baxter,Francesca L. Nice,Gunes Gundem,David C. Wedge,Edward Avezov,Juan Li,Karoline Kollmann,David G. Kent,Athar Aziz,Anna L. Godfrey,Jonathon Hinton,Inigo Martincorena,P Van Loo,Amy V. Jones,Paola Guglielmelli,P. S. Tarpey,Heather P. Harding,J.D. Fitzpatrick,C.T. Goudie,Christina A. Ortmann,Stephen J. Loughran,Keiran Raine,David R. Jones,Adam Butler,Jon W. Teague,Sarah O’Meara,Stuart McLaren,M. Bianchi,Yvonne Silber,D. Dimitropoulou,David Bloxham,L. Mudie,Mark Maddison,Bruce W. S. Robinson,Clodagh Keohane,Cathy MacLean,Kate Hill,Kim Orchard,Sudhir Tauro,Ming-Qing Du,Mel Greaves,David G. Bowen,Brian J. P. Huntly,Claire N. Harrison,Nicholas C.P. Cross,David Ron,Alessandro M. Vannucchi,Elli Papaemmanuil,Peter J. Campbell,Anthony R. Green +51 more
TL;DR: Somatic mutations in the endoplasmic reticulum chaperone CALR were found in a majority of patients with myeloproliferative neoplasms with nonmutated JAK2, a finding consistent with its role as an initiating mutation in some patients.
Journal ArticleDOI
Imatinib for systemic mast-cell disease
Animesh Pardanani,Michelle A. Elliott,Terra L. Reeder,Chin-Yang Li,E J Baxter,Nicholas C.P. Cross,Ayalew Tefferi +6 more
TL;DR: The results suggest that imatinib either inhibits the growth-promoting role of wild type ckit, or targets an oncogenic kinase in patients with symptomatic systemic mast-cell disease.
disorders Imatinib therapy for hypereosinophilic syndrome and other eosinophilic
Ayalew Tefferi,A. Pardanani,Terra L. Reeder,Luis F. Porrata,Chin-Yang Li,Henry D. Tazelaar,E J Baxter +6 more
TL;DR: Although the drug was well tolerated in most patients, a previously unrecognized treatment toxicity of acute left ventricular dysfunction occurred in a responding patient with HES within the first week of treatment.